References
- Liebowitz M, Croft HA, Kajdasz DK, et al. The safety and tolerability profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Psychopharmacol Bull. 2011;44:15–33.
- University of Arizona, December 10, 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT01878292?term=vilazodone+adolescent&rank=1
- Laughren TP, Gobburu J, Temple RJ, et al. Vilazodone: clinical basis for the US Food and Drug Administration’s approval of a new antidepressant. J Clin Psychiatry. 2011;72:1166–1173.
- Acker EC, Sinclair EA, Beardsley AL, et al. Acute vilazodone toxicity in a pediatric patient. J Emerg Med. 2015;49:284–286.
- Carstairs SD, Griffith EA, Alayin T, et al. Recurrent seizure activity in a child after acute vilazodone ingestion. Ann Emerg Med. 2012;60:819–820.
- Mowry JB, Spyker DA, Brooks DE, et al. 2014 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 32nd annual report. Clin Toxicol (Phila). 2015;53:962–1147.
- Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112–1120.
- Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003;96:635–642.
- Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol. 1997;17:208–221.